Cat. Number:

Anti-Neuronatin抗體KL-11519R

Quantity size:

0.2ml

Concentration:

1mg/ml   Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Background:

The paternally imprinted Neuronatin gene (NNAT) is initially expressed in rhombomeres and the pituitary gland and is later expressed more widely, but much less abundantly, in the central and peripheral nervous systems. Anti-Neuronatin抗體The human NNAT gene maps to chromosome 20q11.23 and contains an imprinting region associated with morphological abnormalities and early neonatal lethality. Specifically, hypermethylation of the NNAT gene occurs in both myeloid and lymphoid acute pediatric leukemias and may inhibit NNAT expression. The Neuronatin protein consists of two isoforms, alpha and beta, which are the products of alternative splicing. The alpha form of the Neuronatin gene is encoded by three exons, whereas the beta form is missing the second exon. Neuronatin mRNA expression is abundant in undifferentiated PC-12 cells. Treatment of these cells with nerve growth factor (NGF), which contributes to neuronal differentiation, downregulates Neuronatin mRNA expression. NNAT (-) 1.9 PC-12 cells exhibit an increase in nigericin, rotenone and valinomcin sensitivity; NNAT transfection restores wild-type PC-12 resistance. These results suggests a potential protective role for Neuronatin against toxic insult during development.

Also known as:

Neuronatin; Nnat; NNAT_HUMAN; Anti-Neuronatin抗體Peg 5; Peg5.

Specificity:

Storage:

Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).

Application:

WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  ICC=1:100-500  IF=1:100-500   
Not yet tested in other applications. Anti-Neuronatin抗體
Optimal working dilutions must be determined by the end user.